Kimberly Yonkers to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Kimberly Yonkers has written about Dose-Response Relationship, Drug.
Connection Strength
0.112
-
Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
Score: 0.053
-
Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992 May; 149(5):587-95.
Score: 0.022
-
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr; 85(3):275-82.
Score: 0.013
-
Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
Score: 0.013
-
Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
Score: 0.011